The purpose of this study was to investigate the effects of IBAs
on lung function and 10-km cycling time-trial performance in
trained female EVH+ and EVH− athletes. The major findings of this
project are fourfold: (1) there was a significant increase in FEV1 in
trained female athletes after the inhalation of 400 g of salbutamol,regardless of their EVH status; (2) despite this significant increase
in lung function after the inhalation of salbutamol in female athletes,
mean power output maintained over the duration of a 10-km
cycling time-trial was significantly decreased; (3) there were no
differences in the response to 400 g of salbutamol on lung function
between male and female athletes; and (4) in the salbutamol
time-trial, mean power output and cycling economy were signifi-
cantly reduced and mean VO2 was significantly increased in female
athletes, but not in males.
Multiple studies on male athletes have shown a significant
improvement in lung function after IBA-use without an effect on
athletic performance.6,19,20 This is the first study to report a significant
increase in lung function after IBA-use with a concomitant
decrease in athletic performance in both EVH+ and EVH− female
athletes.
The reduced mean power output in the salbutamol time-trial in
female athletes, representing a potential ergolytic effect of salbutamol
in female athletes, could be explained by an over-stimulation
of the adrenergic 2-system impairing athletic performance. Seventeen
female athletes reported either one or a combination of
the following salbutamol side-effects: tremor, noticeable increase
in resting heart rate, or a feeling of restlessness. In our previous
study with men,6 who were heavier and exposed to the identical
dose of salbutamol (i.e. had a lower dose of salbutamol per
kilogram of body-weight), mean VO2 was not increased in the
salbutamol time-trial and side-effects of salbutamol were reported
in only 5 out of 49 athletes. The increased salbutamol dose per kilogram
of body-weight may also be responsible for the trend for
higher heart rates (especially in the first 8 km of the time-trial)
observed in female athletes after IBA-use compared to male athletes.
In contrast to this hypothesis, Sporer et al.21 did not find
a dose-response relationship with regards to VO2 and HR when
trained male cyclists were exposed to increasing doses (200 g,
400 g and800 g) ofIBA15 minprior to a simulated20-kmcycling
time-trial.
The purpose of this study was to investigate the effects of IBAson lung function and 10-km cycling time-trial performance intrained female EVH+ and EVH− athletes. The major findings of thisproject are fourfold: (1) there was a significant increase in FEV1 intrained female athletes after the inhalation of 400 g of salbutamol,regardless of their EVH status; (2) despite this significant increasein lung function after the inhalation of salbutamol in female athletes,mean power output maintained over the duration of a 10-kmcycling time-trial was significantly decreased; (3) there were nodifferences in the response to 400 g of salbutamol on lung functionbetween male and female athletes; and (4) in the salbutamoltime-trial, mean power output and cycling economy were signifi-cantly reduced and mean VO2 was significantly increased in femaleathletes, but not in males.Multiple studies on male athletes have shown a significantimprovement in lung function after IBA-use without an effect onathletic performance.6,19,20 This is the first study to report a significantincrease in lung function after IBA-use with a concomitantdecrease in athletic performance in both EVH+ and EVH− femaleathletes.The reduced mean power output in the salbutamol time-trial infemale athletes, representing a potential ergolytic effect of salbutamolin female athletes, could be explained by an over-stimulationof the adrenergic 2-system impairing athletic performance. Seventeenfemale athletes reported either one or a combination ofthe following salbutamol side-effects: tremor, noticeable increasein resting heart rate, or a feeling of restlessness. In our previousstudy with men,6 who were heavier and exposed to the identicaldose of salbutamol (i.e. had a lower dose of salbutamol perkilogram of body-weight), mean VO2 was not increased in thesalbutamol time-trial and side-effects of salbutamol were reportedin only 5 out of 49 athletes. The increased salbutamol dose per kilogramof body-weight may also be responsible for the trend forhigher heart rates (especially in the first 8 km of the time-trial)observed in female athletes after IBA-use compared to male athletes.In contrast to this hypothesis, Sporer et al.21 did not finda dose-response relationship with regards to VO2 and HR whentrained male cyclists were exposed to increasing doses (200 g,400 g and800 g) ofIBA15 minprior to a simulated20-kmcyclingtime-trial.
การแปล กรุณารอสักครู่..